25‐hydroxyvitamin D, vitamin D receptor gene polymorphisms, and severity of Parkinson's disease

Suzuki, Masahiko; Yoshioka, Masayuki; Hashimoto, Masaya; Murakami, Maiko; Kawasaki, Kohkichi; Noya, Miki; Takahashi, Daisuke; Urashima, Mitsuyoshi

doi:10.1002/mds.24016

Cited by 84 publications

(82 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A Japanese population exhibited a higher incidence of hip fractures and lower serum levels of 25OHD in PD patients as compared with the healthy controls [34,35], observations that were confirmed in a Caucasian population [9]. The serum 25OHD level correlated negatively with the severity of PD, measured in terms of the Hoehn &Yahr stage and the Unified Parkinson's Disease Rating Scale (UPDRS) [34][35][36].…”

Section: Introductionmentioning

confidence: 81%

“…Whereas Sato et al [34] reported a negative correlation between the 1,25OHD level and the UPDRS score, Suzuki et al [36] could not confirm this finding.…”

Section: Introductionmentioning

confidence: 86%

“…Differences have also been demonstrated in the VDR polymorphisms in PD in Japanese, Korean, Chinese and Caucasian populations [6,12,18,36].…”

Section: Vdr Apai Polymorphismmentioning

confidence: 98%

“…In Japan, FokI CC genotype was associated with milder forms of PD [36]. Han et al [12] suggested that FokI C allele might be a risk factor for sporadic PD development.…”

Section: Vdr Apai Polymorphismmentioning

confidence: 99%

“…Suzuki et al [36] found that FokI CC genotype was associated with milder forms of PD in a Japanese population. Furthermore, an association between the BsmI bb genotype and PD was demonstrated in a Korean population [18].…”

Section: Introductionmentioning

confidence: 98%

See 4 more Smart Citations

Association of vitamin D receptor gene polymorphisms and Parkinson's disease in Hungarians

Török

Szalárdy

et al. 2013

Neuroscience Letters

View full text Add to dashboard Cite

Vitamin D receptor (VDR) gene encodes a transcription factor that influences calcium homeostasis and immunoregulation, and may play a role in neurological disorders including Parkinson's disease (PD). The investigations of the association between VDR and PD in different populations revealed various results. In a present study 100 PD patients and 109 healthy controls from the Hungarian population were genotyped for four polymorphic sites (BsmI, ApaI, FokI and TaqI) in the VDR gene. The polymorphisms were determined by polymerase chain reaction and restriction fragment length polymorphism (PCR-RFLP). Our results demonstrate an association between the FokI C allele and PD; the frequency of the C allele was significantly higher in PD patients than in controls, suggesting that this polymorphism may have a role in the development of PD in these patients.

show abstract

Section: Introductionmentioning

confidence: 81%

“…Whereas Sato et al [34] reported a negative correlation between the 1,25OHD level and the UPDRS score, Suzuki et al [36] could not confirm this finding.…”

Section: Introductionmentioning

confidence: 86%

“…Differences have also been demonstrated in the VDR polymorphisms in PD in Japanese, Korean, Chinese and Caucasian populations [6,12,18,36].…”

Section: Vdr Apai Polymorphismmentioning

confidence: 98%

“…In Japan, FokI CC genotype was associated with milder forms of PD [36]. Han et al [12] suggested that FokI C allele might be a risk factor for sporadic PD development.…”

Section: Vdr Apai Polymorphismmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 98%

See 3 more Smart Citations

Association of vitamin D receptor gene polymorphisms and Parkinson's disease in Hungarians

Török

Szalárdy

et al. 2013

Neuroscience Letters

View full text Add to dashboard Cite

show abstract

Effect of Vitamin D Supplementation on Relapse-Free Survival Among Patients With Digestive Tract Cancers

Urashima

Ohdaira

Akutsu

et al. 2019

JAMA

Self Cite

111

131

View full text Add to dashboard Cite

IMPORTANCE Randomized clinical trials of vitamin D supplementation for secondary prevention in patients with cancer are needed, given positive results of observational studies. OBJECTIVE To determine whether postoperative vitamin D 3 supplementation can improve survival of patients with digestive tract cancers overall and in subgroups stratified by 25-hydroxyvitamin D (25[OH]D) levels. DESIGN, SETTING, AND PARTICIPANTS The AMATERASU trial, a randomized, double-blind, placebo-controlled trial conducted at a single university hospital in Japan. Enrollment began in January 2010 and follow-up was completed in February 2018. Patients aged 30 to 90 years with cancers of the digestive tract from the esophagus to the rectum, stages I to III, were recruited. Of 439 eligible patients, 15 declined and 7 were excluded after operation. INTERVENTIONS Patients were randomized to receive oral supplemental capsules of vitamin D (2000 IU/d; n = 251) or placebo (n = 166) from the first postoperative outpatient visit to until the end of the trial. MAIN OUTCOMES AND MEASURES The primary outcome was relapse-free survival time to relapse or death. The secondary outcome was overall survival time to death due to any cause. Subgroups analyzed had baseline serum 25(OH)D levels of 0 to less than 20 ng/mL, 20 to 40 ng/mL, and greater than 40 ng/mL; because of small sample size for the highest-baselinelevel group, interactions were tested only between the low-and middle-baseline-level groups. RESULTS All 417 randomized patients (mean age, 66 years; male, 66%; esophageal cancer, 10%; gastric cancer, 42%; colorectal cancer, 48%) were included in the analyses. There was 99.8% follow-up over a median 3.5 (interquartile range, 2.3-5.3) years, with maximal follow-up of 7.6 years. Relapse or death occurred in 50 patients (20%) randomized to vitamin D and 43 patients (26%) randomized to placebo. Death occurred in 37 (15%) in the vitamin D group and 25 (15%) in the placebo group. The 5-year relapse-free survival was 77% with vitamin D vs 69% with placebo (hazard ratio [HR] for relapse or death, 0.76; 95% CI, 0.50-1.14; P = .18). The 5-year overall survival in the vitamin D vs placebo groups was 82% vs 81% (HR for death, 0.95; 95% CI, 0.57-1.57; P = .83). In the subgroup of patients with baseline serum 25(OH)D levels between 20 and 40 ng/mL, the 5-year relapse-free survival was 85% with vitamin D vs 71% with placebo (HR for relapse or death, 0.46; 95% CI, 0.24-0.86; P = .02; P = .04 for interaction). Fractures occurred in 3 patients (1.3%) in the vitamin D group and 5 (3.4%) in the placebo group. Urinary stones occurred in 2 patients (0.9%) in the vitamin D group and 0 in the placebo group. CONCLUSIONS AND RELEVANCE Among patients with digestive tract cancer, vitamin D supplementation, compared with placebo, did not result in significant improvement in relapse-free survival at 5 years.

show abstract

Vitamin D and Parkinson's disease

Lương

Nguyễn

2012

J of Neuroscience Research

View full text Add to dashboard Cite

Parkinson's disease (PD) is the second most common form of neurodegeneration among the elderly population. PD is clinically characterized by tremors, rigidity, slowness of movement, and postural imbalance. Interestingly, a significant association has been demonstrated between PD and low levels of vitamin D in the serum, and vitamin D supplement appears to have a beneficial clinical effect on PD. Genetic studies have provided the opportunity to determine which proteins link vitamin D to PD pathology, e.g., Nurr1 gene, toll-like receptor, gene related to lipid disorders, vascular endothelial factor, tyrosine hydroxylase, and angiogenin. Vitamin D also exerts its effects on cancer through nongenomic factors, e.g., bacillus Calmette-Guerin vaccination, interleukin-10, Wntβ-catenin signaling pathways, mitogen-activated protein kinase pathways, and the reduced form of the nicotinamide adenine dinucleotide phosphate. In conclusion, vitamin D might have a beneficial role in PD. Calcitriol is best used for PD because it is the active form of the vitamin D(3) metabolite and modulates inflammatory cytokine expression. Further investigation with calcitriol in PD is needed.

show abstract

25‐hydroxyvitamin D, vitamin D receptor gene polymorphisms, and severity of Parkinson's disease

Cited by 84 publications

References 32 publications

Association of vitamin D receptor gene polymorphisms and Parkinson's disease in Hungarians

Association of vitamin D receptor gene polymorphisms and Parkinson's disease in Hungarians

Effect of Vitamin D Supplementation on Relapse-Free Survival Among Patients With Digestive Tract Cancers

Vitamin D and Parkinson's disease

Contact Info

Product

Resources

About